Teva Pharmaceuticals has officially finalized its acquisition of assets from BioXcel Therapeutics, marking a significant consolidation in the neuroscience sector. The transaction, which was initially unveiled in August 2026, concludes a turbulent period for BioXcel, which filed for Chapter 11 bankruptcy in the United States as part of the asset sale agreement.
Under the terms of the deal, Teva has paid $57.5 million upfront, with provisions for an additional $10 million in contingent payments, bringing the potential total value of the acquisition to $67.5 million.
The centerpiece of this acquisition is BXCL501, an investigational sublingual film of dexmedetomidine currently under rigorous review by the U.S. Food and Drug Administration (FDA). If approved, BXCL501 is poised to become the first at-home treatment for acute agitation associated with schizophrenia or bipolar I and II disorder.
Industry experts note that between 25% and 40% of patients suffering from these psychiatric conditions experience episodes of acute agitation. Currently, treatment options are largely confined to medical facilities, leaving a critical gap in care for patients who need intervention before a crisis escalates.
“Agitation can escalate quickly, which is why the ability to intervene early matters,” said Eric Hughes, MD, PhD, Teva’s Executive Vice President of Global R&D and Chief Medical Officer. “BXCL501 could give adults living with schizophrenia or bipolar I or II disorder the ability to treat agitation at home—closer to the moment symptoms emerge, and before they could become more difficult to manage.”
In addition to the late-stage candidate BXCL501, the acquisition includes Igalmi (dexmedetomidine), which is already FDA-approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. While Igalmi is currently indicated for use within a hospital or clinical setting, the addition of BXCL501 into the Teva pipeline suggests a strategic push to migrate this treatment modality into the patient’s home environment.
For Teva, the acquisition is a targeted move to bolster its footprint in neurology and psychiatry. Evan Lippman, Teva’s Executive Vice President of Business Development, emphasized that the purchase aligns with the company’s broader strategy of investing in high-potential, late-stage assets that address clear medical needs.
“BXCL501 is a strong strategic fit with our neuroscience portfolio,” Lippman stated. “[It] reflects our disciplined focus on differentiated, late-stage opportunities that address unmet patient needs and create long-term value for shareholders.”
As Teva moves to integrate these new assets, the pharmaceutical market remains closely focused on the pending FDA decision regarding BXCL501, which, if successful, could redefine the standard of care for thousands of patients living with severe psychiatric agitation.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
